Eli Lilly: Hidden Growth Drivers Beyond Weight-Loss Drugs

While the market focuses on a single class of blockbuster drugs, a different story is unfolding inside Eli Lilly (NYSE: LLY). According to a Trefis analysis, the company's immunology, oncology, and neuroscience medicines are compounding at a blistering pace. These other therapeutic areas collectively grew by 160% last quarter, a rate that suggests a much broader growth engine is taking shape.

Rating Change

No explicit rating change was issued, but the analysis highlights upside potential from underappreciated growth drivers.

Analyst Rationale

Analysts believe the market's singular focus on obesity drugs like Mounjaro and Zepbound may overlook the strength of Lilly's other pipelines. The 160% growth in immunology, oncology, and neuroscience indicates a diversified portfolio that could reduce risk and support a higher valuation.

Context

LLY stock has surged over the past year on the back of its weight-loss drugs, but analysts are now looking beyond that. Compared to peers such as JNJ, ABBV, MRK, PFE, and AMGN, Lilly's diversified pipeline offers a competitive edge.

Conclusion

While obesity drugs remain the headline, the robust growth in other therapeutic areas strengthens Lilly's fundamentals and provides a compelling case for investors seeking diversified exposure.